Amicus Therapeutics Financial Statements (FOLD)
|
|
Report date
|
|
|
02.03.2020 |
01.03.2021 |
24.02.2022 |
01.03.2023 |
28.02.2024 |
|
06.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
182.2 |
260.9 |
305.5 |
329.2 |
399.4 |
|
493.7 |
Operating Income, bln rub |
|
|
-300.7 |
-243.9 |
-199.9 |
-204.4 |
-73.5 |
|
11.3 |
EBITDA, bln rub |
? |
|
-332.3 |
-243.0 |
-202.9 |
-199.6 |
-92.1 |
|
-9.20 |
Net profit, bln rub |
? |
|
-356.4 |
-276.9 |
-250.5 |
-236.6 |
-151.6 |
|
-104.7 |
|
OCF, bln rub |
? |
|
-250.4 |
-233.3 |
-202.5 |
-166.6 |
-69.1 |
|
3.46 |
CAPEX, bln rub |
? |
|
20.0 |
3.23 |
3.88 |
3.77 |
7.44 |
|
7.55 |
FCF, bln rub |
? |
|
-270.4 |
-236.5 |
-206.4 |
-170.3 |
-76.5 |
|
1.73 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
461.0 |
473.7 |
471.0 |
495.1 |
427.7 |
|
421.2 |
Cost of production, bln rub |
|
|
22.0 |
31.0 |
34.5 |
38.6 |
37.3 |
|
55.9 |
R&D, bln rub |
|
|
286.4 |
308.4 |
272.0 |
276.7 |
152.4 |
|
114.2 |
Interest expenses, bln rub |
|
|
18.9 |
22.4 |
32.5 |
37.1 |
50.1 |
|
50.5 |
|
Assets, bln rub |
|
|
850.2 |
886.5 |
905.1 |
724.2 |
777.9 |
|
786.6 |
Net Assets, bln rub |
? |
|
476.4 |
286.4 |
307.4 |
123.0 |
160.2 |
|
178.8 |
Debt, bln rub |
|
|
210.2 |
441.7 |
440.1 |
452.1 |
445.1 |
|
444.7 |
Cash, bln rub |
|
|
452.7 |
483.3 |
482.5 |
293.6 |
286.2 |
|
249.8 |
Net debt, bln rub |
|
|
-242.5 |
-41.5 |
-42.4 |
158.5 |
158.9 |
|
194.9 |
|
Ordinary share price, rub |
|
|
9.74 |
23.1 |
11.6 |
12.2 |
14.2 |
|
10.9 |
Number of ordinary shares, mln |
|
|
240.4 |
258.9 |
271.4 |
289.1 |
295.2 |
|
304.7 |
|
Market cap, bln rub |
|
|
2 342 |
5 977 |
3 135 |
3 529 |
4 188 |
|
3 333 |
EV, bln rub |
? |
|
2 099 |
5 936 |
3 093 |
3 688 |
4 347 |
|
3 528 |
Book value, bln rub |
|
|
256 |
66 |
87 |
-98 |
-58 |
|
-37 |
|
EPS, rub |
? |
|
-1.48 |
-1.07 |
-0.92 |
-0.82 |
-0.51 |
|
-0.34 |
FCF/share, rub |
|
|
-1.12 |
-0.91 |
-0.76 |
-0.59 |
-0.26 |
|
0.01 |
BV/share, rub |
|
|
1.06 |
0.25 |
0.32 |
-0.34 |
-0.20 |
|
-0.12 |
|
EBITDA margin, % |
? |
|
-182.3% |
-93.1% |
-66.4% |
-60.6% |
-23.1% |
|
-1.86% |
Net margin, % |
? |
|
-195.6% |
-106.1% |
-82.0% |
-71.9% |
-38.0% |
|
-21.2% |
FCF yield, % |
? |
|
-11.5% |
-3.96% |
-6.58% |
-4.83% |
-1.83% |
|
0.05% |
ROE, % |
? |
|
-74.8% |
-96.7% |
-81.5% |
-192.3% |
-94.6% |
|
-58.5% |
ROA, % |
? |
|
-41.9% |
-31.2% |
-27.7% |
-32.7% |
-19.5% |
|
-13.3% |
|
P/E |
? |
|
-6.57 |
-21.6 |
-12.5 |
-14.9 |
-27.6 |
|
-31.8 |
P/FCF |
|
|
-8.66 |
-25.3 |
-15.2 |
-20.7 |
-54.7 |
|
1 930 |
P/S |
? |
|
12.8 |
22.9 |
10.3 |
10.7 |
10.5 |
|
6.75 |
P/BV |
? |
|
9.16 |
91.1 |
36.2 |
-36.1 |
-72.1 |
|
-90.1 |
EV/EBITDA |
? |
|
-6.32 |
-24.4 |
-15.2 |
-18.5 |
-47.2 |
|
-383.7 |
Debt/EBITDA |
|
|
0.73 |
0.17 |
0.21 |
-0.79 |
-1.73 |
|
-21.2 |
|
R&D/CAPEX, % |
|
|
1 431% |
9 558% |
7 004% |
7 347% |
2 048% |
|
1 513% |
|
CAPEX/Revenue, % |
|
|
11.0% |
1.24% |
1.27% |
1.14% |
1.86% |
|
1.53% |
|
Amicus Therapeutics shareholders |